IL-1 and IFN-gamma increase vascular permeability.
PDF (885K)
Journal: 1988/August - Immunology
ISSN: 0019-2805
PUBMED: 3134297
Abstract:
We examined the effect of cytokines on vascular permeability in vivo. Wistar rats received intradermal injections of various cytokine preparations and the permeability index (delta PI) was calculated from the difference between the absorption values of cytokine- and vehicle-treated skin sections after the extraction of accumulated Evans blue vital dye. Injections of a mixture of recombinant interleukin-1 alpha and beta (Il-1 alpha, IL-1 beta) and interferon-gamma (IFN-gamma) caused a maximal increase of permeability after 30 min (delta PI = 2). The administration of single recombinant cytokines revealed that the increase of permeability is mainly due to the action of IL-1 beta (delta PI = 1.4) and IFN-gamma (delta PI = 2.9) (P less than 0.001) at doses of 1-20 microU per injection site. IL-1 alpha slightly increased vascular permeability, whereas recombinant IL-2 and recombinant tumour necrosis factor alpha had no significant effects. Histological observations revealed significantly increased numbers of degranulated mast cells in skin sections pretreated with IL-1 beta (P less than 0.005) or IFN-gamma (P less than 0.001). The cytokine-mediated rise of vascular permeability could be suppressed by pretreatment of the animals with the vasoactive amine antagonizing drugs methysergide, pizotifen and cyproheptadine. Our experiments indicate an important role of IL-1 beta and IFN-gamma as vasoactive substances besides their function as hormone-like messengers between leucocytes.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(37)
References
(31)
Drugs
(1)
Chemicals
(6)
Organisms
(3)
Processes
(1)
Anatomy
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Immunology 64(2): 301-305
PMID: 3134297

IL-1 and IFN-gamma increase vascular permeability.

Abstract

We examined the effect of cytokines on vascular permeability in vivo. Wistar rats received intradermal injections of various cytokine preparations and the permeability index (delta PI) was calculated from the difference between the absorption values of cytokine- and vehicle-treated skin sections after the extraction of accumulated Evans blue vital dye. Injections of a mixture of recombinant interleukin-1 alpha and beta (Il-1 alpha, IL-1 beta) and interferon-gamma (IFN-gamma) caused a maximal increase of permeability after 30 min (delta PI = 2). The administration of single recombinant cytokines revealed that the increase of permeability is mainly due to the action of IL-1 beta (delta PI = 1.4) and IFN-gamma (delta PI = 2.9) (P less than 0.001) at doses of 1-20 microU per injection site. IL-1 alpha slightly increased vascular permeability, whereas recombinant IL-2 and recombinant tumour necrosis factor alpha had no significant effects. Histological observations revealed significantly increased numbers of degranulated mast cells in skin sections pretreated with IL-1 beta (P less than 0.005) or IFN-gamma (P less than 0.001). The cytokine-mediated rise of vascular permeability could be suppressed by pretreatment of the animals with the vasoactive amine antagonizing drugs methysergide, pizotifen and cyproheptadine. Our experiments indicate an important role of IL-1 beta and IFN-gamma as vasoactive substances besides their function as hormone-like messengers between leucocytes.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (885K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
icon of scanned page 301
301
icon of scanned page 302
302
icon of scanned page 303
303
icon of scanned page 304
304
icon of scanned page 305
305

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Arthur GP, Hornabrook RW. The treatment of migraine with BC 105 (pizotifen): a double blind trial. N Z Med J. 1971 Jan;73(464):5–9. [PubMed] [Google Scholar]
  • Askenase PW, Metzler CM, Gershon RK. Localization of leucocytes in sites of delayed-type hypersensitivity and in lymph nodes: dependence on vasoactive amines. Immunology. 1982 Oct;47(2):239–246.[PMC free article] [PubMed] [Google Scholar]
  • Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science. 1986 Jun 20;232(4757):1545–1547. [PubMed] [Google Scholar]
  • Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA., Jr Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest. 1985 Nov;76(5):2003–2011.[PMC free article] [PubMed] [Google Scholar]
  • Choi KL, Sauder DN. The role of Langerhans cells and keratinocytes in epidermal immunity. J Leukoc Biol. 1986 Mar;39(3):343–358. [PubMed] [Google Scholar]
  • Cybulsky MI, Colditz IG, Movat HZ. The role of interleukin-1 in neutrophil leukocyte emigration induced by endotoxin. Am J Pathol. 1986 Sep;124(3):367–372.[PMC free article] [PubMed] [Google Scholar]
  • Dower SK, Kronheim SR, Hopp TP, Cantrell M, Deeley M, Gillis S, Henney CS, Urdal DL. The cell surface receptors for interleukin-1 alpha and interleukin-1 beta are identical. Nature. 1986 Nov 20;324(6094):266–268. [PubMed] [Google Scholar]
  • Granstein RD, Margolis R, Mizel SB, Sauder DN. In vivo inflammatory activity of epidermal cell-derived thymocyte activating factor and recombinant interleukin 1 in the mouse. J Clin Invest. 1986 Mar;77(3):1020–1027.[PMC free article] [PubMed] [Google Scholar]
  • Hauser C, Saurat JH, Schmitt A, Jaunin F, Dayer JM. Interleukin 1 is present in normal human epidermis. J Immunol. 1986 May 1;136(9):3317–3323. [PubMed] [Google Scholar]
  • HAYASHI H, YOSHINAGA M, KOONO M, MIYOSHI H, MATSUMURA M. ENDOGENEOUS PERMEABILITY FACTORS AND THEIR INHIBITORS AFFECTING VASCULAR PERMEABILITY IN CUTANEOUS ARTHUS REACTIONS AND THERMAL INJURY. Br J Exp Pathol. 1964 Aug;45:419–435.[PMC free article] [PubMed] [Google Scholar]
  • Hughes RC, Foster JB. BC 105 in the prophylaxis of migraine. Curr Ther Res Clin Exp. 1971 Jan;13(1):63–68. [PubMed] [Google Scholar]
  • JUDAH JD, WILLOUGHBY DA. A quantitative method for the study of capillary permeability: extraction and determination of trypan blue in tissues. J Pathol Bacteriol. 1962 Apr;83:567–572. [PubMed] [Google Scholar]
  • Linthicum DS. Development of acute autoimmune encephalomyelitis in mice: factors regulating the effector phase of the disease. Immunobiology. 1982 Aug;162(3):211–220. [PubMed] [Google Scholar]
  • Linthicum DS, Munoz JJ, Blaskett A. Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell Immunol. 1982 Nov 1;73(2):299–310. [PubMed] [Google Scholar]
  • Luger TA, Stadler BM, Katz SI, Oppenheim JJ. Epidermal cell (keratinocyte)-derived thymocyte-activating factor (ETAF). J Immunol. 1981 Oct;127(4):1493–1498. [PubMed] [Google Scholar]
  • Matsubara T, Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines. J Immunol. 1986 Nov 15;137(10):3295–3298. [PubMed] [Google Scholar]
  • Montesano R, Orci L, Vassalli P. Human endothelial cell cultures: phenotypic modulation by leukocyte interleukins. J Cell Physiol. 1985 Mar;122(3):424–434. [PubMed] [Google Scholar]
  • Nathan CF, Kaplan G, Levis WR, Nusrat A, Witmer MD, Sherwin SA, Job CK, Horowitz CR, Steinman RM, Cohn ZA. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med. 1986 Jul 3;315(1):6–15. [PubMed] [Google Scholar]
  • Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986 Jun 1;163(6):1363–1375.[PMC free article] [PubMed] [Google Scholar]
  • Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol. 1985 Dec;135(6):3962–3968. [PubMed] [Google Scholar]
  • Peet KM. Use of pizotifen in severe migraine: a long-term study. Curr Med Res Opin. 1977;5(2):192–199. [PubMed] [Google Scholar]
  • Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA., Jr Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol. 1986 Mar 1;136(5):1680–1687. [PubMed] [Google Scholar]
  • Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986 Sep 1;137(5):1735–1742. [PubMed] [Google Scholar]
  • Sauder DN, Dinarello CA, Morhenn VB. Langerhans cell production of interleukin-1. J Invest Dermatol. 1984 Jun;82(6):605–607. [PubMed] [Google Scholar]
  • Schmitt A, Hauser C, Jaunin F, Dayer JM, Saurat JH. Normal epidermis contains high amounts of natural tissue IL 1 biochemical analysis by HPLC identifies a MW approximately 17 Kd form with a P1 5.7 and a MW approximately 30 Kd form. Lymphokine Res. 1986 Spring;5(2):105–118. [PubMed] [Google Scholar]
  • Schwab E, Burkart V, Freytag G, Kiesel U, Kolb H. Inhibition of immune-mediated low-dose streptozotocin diabetes by agents which reduce vascular permeability. Immunopharmacology. 1986 Aug;12(1):17–21. [PubMed] [Google Scholar]
  • Stolpen AH, Guinan EC, Fiers W, Pober JS. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol. 1986 Apr;123(1):16–24.[PMC free article] [PubMed] [Google Scholar]
  • Subramanian N, Bray MA. Interleukin 1 releases histamine from human basophils and mast cells in vitro. J Immunol. 1987 Jan 1;138(1):271–275. [PubMed] [Google Scholar]
  • Udaka K, Takeuchi Y, Movat HZ. Simple method for quantitation of enhanced vascular permeability. Proc Soc Exp Biol Med. 1970 Apr;133(4):1384–1387. [PubMed] [Google Scholar]
  • Van Loveren H, Kraeuter-Kops S, Askenase PW. Different mechanisms of release of vasoactive amines by mast cells occur in T cell-dependent compared to IgE-dependent cutaneous hypersensitivity responses. Eur J Immunol. 1984 Jan;14(1):40–47. [PubMed] [Google Scholar]
  • Yu CL, Haskard DO, Cavender D, Johnson AR, Ziff M. Human gamma interferon increases the binding of T lymphocytes to endothelial cells. Clin Exp Immunol. 1985 Dec;62(3):554–560.[PMC free article] [PubMed] [Google Scholar]
Diabetes Research Institute, University of Düsseldorf, FRG.
Diabetes Research Institute, University of Düsseldorf, FRG.
Copyright notice
Abstract
We examined the effect of cytokines on vascular permeability in vivo. Wistar rats received intradermal injections of various cytokine preparations and the permeability index (delta PI) was calculated from the difference between the absorption values of cytokine- and vehicle-treated skin sections after the extraction of accumulated Evans blue vital dye. Injections of a mixture of recombinant interleukin-1 alpha and beta (Il-1 alpha, IL-1 beta) and interferon-gamma (IFN-gamma) caused a maximal increase of permeability after 30 min (delta PI = 2). The administration of single recombinant cytokines revealed that the increase of permeability is mainly due to the action of IL-1 beta (delta PI = 1.4) and IFN-gamma (delta PI = 2.9) (P less than 0.001) at doses of 1-20 microU per injection site. IL-1 alpha slightly increased vascular permeability, whereas recombinant IL-2 and recombinant tumour necrosis factor alpha had no significant effects. Histological observations revealed significantly increased numbers of degranulated mast cells in skin sections pretreated with IL-1 beta (P less than 0.005) or IFN-gamma (P less than 0.001). The cytokine-mediated rise of vascular permeability could be suppressed by pretreatment of the animals with the vasoactive amine antagonizing drugs methysergide, pizotifen and cyproheptadine. Our experiments indicate an important role of IL-1 beta and IFN-gamma as vasoactive substances besides their function as hormone-like messengers between leucocytes.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.